{"transactions":[{"id":4716,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T21:00:28.000Z","date":"2026-09-02","kind":"grant","planned":true,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant."}],"balance_after":27000,"derivative":{"exercise_price":1,"expiration_date":"2036-09-02","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001213900-26-097742","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000121390026097742/ownership.xml","form_type":"4"}},{"id":4715,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T21:00:28.000Z","date":"2026-09-02","kind":"grant","planned":true,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001213900-26-097742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000121390026097742/ownership.xml","form_type":"4"}},{"id":940538,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T01:29:29.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":13.3,"exercise_date":"2027-01-09","expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001492647-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000149264726000001/primary_doc.xml","form_type":"4"}},{"id":993320,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T23:16:44.000Z","date":"2025-11-18","kind":"purchase","planned":false,"acquired":true,"shares":1900,"price":7.5157,"value":14279.83,"ownership":{"direct":false,"nature":"By Meadowlark Management, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.45 to $7.70. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein."}],"balance_after":1993,"source":{"system":"sec-edgar","filing":"0001492647-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000149264725000004/primary_doc.xml","form_type":"4/A","original_submission_date":"2025-11-19"}},{"id":993319,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T23:16:44.000Z","date":"2025-11-17","kind":"purchase","planned":false,"acquired":true,"shares":93,"price":7.15,"value":664.95,"ownership":{"direct":false,"nature":"By Meadowlark Management, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein."}],"balance_after":93,"source":{"system":"sec-edgar","filing":"0001492647-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000149264725000004/primary_doc.xml","form_type":"4/A","original_submission_date":"2025-11-19"}},{"id":994934,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-19T23:43:46.000Z","date":"2025-11-18","kind":"purchase","planned":false,"acquired":true,"shares":1900,"price":7.5157,"value":14279.83,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $7.45 to $7.70. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":1993,"source":{"system":"sec-edgar","filing":"0001492647-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000149264725000003/primary_doc.xml","form_type":"4"}},{"id":994933,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-19T23:43:46.000Z","date":"2025-11-17","kind":"purchase","planned":false,"acquired":true,"shares":93,"price":7.15,"value":664.95,"ownership":{"direct":true},"balance_after":93,"source":{"system":"sec-edgar","filing":"0001492647-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000149264725000003/primary_doc.xml","form_type":"4"}},{"id":1093931,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T12:14:05.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80000,"derivative":{"exercise_price":5.75,"exercise_date":"2026-07-01","expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001654954-25-007739","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007739/section16.xml","form_type":"4"}},{"id":1106237,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T16:13:21.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date."}],"balance_after":20100,"derivative":{"exercise_price":4.47,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001578563-25-000319","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000157856325000319/primary_doc.xml","form_type":"4"}},{"id":1183335,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T18:22:02.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":1.71,"expiration_date":"2034-11-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-25-028230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000121390025028230/ownership.xml","form_type":"4"}},{"id":1186387,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-01T16:22:37.000Z","date":"2025-03-28","kind":"exercise","planned":false,"acquired":false,"shares":3167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":6333,"derivative":{"underlying":"Common Stock","underlying_shares":3167},"source":{"system":"sec-edgar","filing":"0001578563-25-000199","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000157856325000199/primary_doc.xml","form_type":"4"}},{"id":1186386,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-01T16:22:37.000Z","date":"2025-03-28","kind":"exercise","planned":false,"acquired":true,"shares":3167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":3167,"source":{"system":"sec-edgar","filing":"0001578563-25-000199","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000157856325000199/primary_doc.xml","form_type":"4"}},{"id":1334915,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T00:49:12.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-24-015471","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424015471/section16.xml","form_type":"4"}},{"id":1365078,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-14T17:21:55.000Z","date":"2024-11-13","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":13,"value":6500.0,"ownership":{"direct":false,"nature":"By Meadowlark Management, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001578563-24-000441","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000157856324000441/primary_doc.xml","form_type":"4"}},{"id":1365077,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-14T17:21:55.000Z","date":"2024-11-12","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":12.499,"value":6249.5,"ownership":{"direct":false,"nature":"By Meadowlark Management, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades ranging from $12.00 to $12.50. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein."}],"balance_after":500,"source":{"system":"sec-edgar","filing":"0001578563-24-000441","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000157856324000441/primary_doc.xml","form_type":"4"}},{"id":1375378,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-05T17:12:03.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents a grant of stock options granted in connection with the Reporting Person's appointment as a director of the Issuer's Board of Directors. The exercise price represents the closing stock price of the Issuer's common stock, par value $0.001 per share, on November 1, 2024, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest as follows: (i) 28% of the options shall vest on the 12-month anniversary of the date of grant, and (ii) 2% of the options shall vest each month from the date of grant, until fully vested."}],"balance_after":50000,"derivative":{"exercise_price":1.71,"expiration_date":"2034-11-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-24-094632","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000121390024094632/ownership.xml","form_type":"4"}},{"id":1433599,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-08-14T16:47:34.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock upon the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":9500,"derivative":{"underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001578563-24-000368","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000157856324000368/primary_doc.xml","form_type":"4"}},{"id":1433598,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-14T16:47:34.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":24600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":24600,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":24600},"source":{"system":"sec-edgar","filing":"0001578563-24-000368","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000157856324000368/primary_doc.xml","form_type":"4"}},{"id":1702138,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-21T16:04:27.000Z","date":"2023-12-20","kind":"grant","planned":false,"acquired":true,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option will vest in full on December 20, 2024, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":3334,"derivative":{"exercise_price":0.043,"exercise_date":"2024-12-20","expiration_date":"2033-12-20","underlying":"Common Stock","underlying_shares":3334},"source":{"system":"sec-edgar","filing":"0001628280-23-042492","document":"wk-form4_1703192659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000162828023042492/wk-form4_1703192659.xml","form_type":"4"}},{"id":1836088,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T16:05:46.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":4575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the stock option will immediately vest on the date that it is granted."}],"balance_after":4575,"derivative":{"exercise_price":0.3552,"exercise_date":"2023-06-30","expiration_date":"2033-06-30","underlying":"Common Stock","underlying_shares":4575},"source":{"system":"sec-edgar","filing":"0001628280-23-024230","document":"wk-form4_1688587518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000162828023024230/wk-form4_1688587518.xml","form_type":"4"}},{"id":1928036,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-04T16:09:59.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":1167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the stock option will immediately vest on the date that it is granted."}],"balance_after":1167,"derivative":{"exercise_price":1.75,"exercise_date":"2023-03-31","expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":1167},"source":{"system":"sec-edgar","filing":"0001628280-23-010589","document":"wf-form4_168063897592978.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000162828023010589/wf-form4_168063897592978.xml","form_type":"4"}},{"id":2072580,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-03T16:11:46.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the stock option will immediately vest on the date that it is granted."}],"balance_after":410,"derivative":{"exercise_price":5.0401,"exercise_date":"2022-12-30","expiration_date":"2032-12-30","underlying":"Common Stock","underlying_shares":410},"source":{"system":"sec-edgar","filing":"0001628280-23-000082","document":"wf-form4_167278029177365.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000162828023000082/wf-form4_167278029177365.xml","form_type":"4"}},{"id":2147286,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-03T16:28:36.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":605,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the stock option will immediately vest on the date that it is granted."}],"balance_after":605,"derivative":{"exercise_price":3.32,"exercise_date":"2022-09-30","expiration_date":"2032-09-30","underlying":"Common Stock","underlying_shares":605},"source":{"system":"sec-edgar","filing":"0001628280-22-025858","document":"wf-form4_166482890030466.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000162828022025858/wf-form4_166482890030466.xml","form_type":"4"}},{"id":2217253,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T16:00:36.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":4338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the stock option will immediately vest on the date that it is granted."}],"balance_after":4338,"derivative":{"exercise_price":0.5,"exercise_date":"2022-06-30","expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":4338},"source":{"system":"sec-edgar","filing":"0001578563-22-000024","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000157856322000024/primary_doc.xml","form_type":"4"}},{"id":2231444,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-15T16:15:32.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option will vest in full on June 14, 2023, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.441,"exercise_date":"2023-06-14","expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001578563-22-000020","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000157856322000020/primary_doc.xml","form_type":"4"}},{"id":2237055,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T00:36:49.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":0.62,"exercise_date":"2023-06-09","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-22-008233","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422008233/section16.xml","form_type":"4"}},{"id":2308137,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-04T17:13:38.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":2985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the stock option will immediately vest on the date that it is granted."}],"balance_after":2985,"derivative":{"exercise_price":0.7247,"exercise_date":"2022-03-31","expiration_date":"2032-03-31","underlying":"Common Stock","underlying_shares":2985},"source":{"system":"sec-edgar","filing":"0001578563-22-000009","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000157856322000009/primary_doc.xml","form_type":"4"}},{"id":2449050,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-04T16:28:13.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":737,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":737,"derivative":{"exercise_price":1.7,"exercise_date":"2021-12-31","expiration_date":"2031-12-31","underlying":"Common Stock","underlying_shares":737},"source":{"system":"sec-edgar","filing":"0001062993-22-000250","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000106299322000250/form4.xml","form_type":"4"}},{"id":2468047,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T22:02:35.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001104659-21-151214","document":"tm2135659-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921151214/tm2135659-3_4seq1.xml","form_type":"4"}},{"id":2477582,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T01:00:45.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded in connection with the Company's 2020 Annual Meeting of Stockholders pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001104659-21-148745","document":"tm2135032-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148745/tm2135032-1_4.xml","form_type":"4"}},{"id":2515036,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-12T16:18:53.000Z","date":"2021-11-10","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in three substantially equal installments on November 10, 2022, November 10, 2023 and November 10, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":2.28,"expiration_date":"2031-11-10","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001878894-21-000022","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000187889421000022/edgar.xml","form_type":"4"}},{"id":2669471,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T20:34:34.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6250,"derivative":{"exercise_price":2,"exercise_date":"2022-06-10","expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001654954-21-006930","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006930/section16.xml","form_type":"4"}},{"id":3271037,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-14T22:00:27.000Z","date":"2019-12-12","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded on December 12, 2019 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001104659-20-021982","document":"tm205737d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920021982/tm205737d2_4.xml","form_type":"4"}},{"id":3700881,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-08T14:00:23.000Z","date":"2019-01-04","kind":"purchase","acquired":true,"shares":1475,"price":3.39,"value":5000.25,"ownership":{"direct":false,"nature":"By Meadowlark Management LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose."}],"balance_after":7175,"source":{"system":"sec-edgar","filing":"0001144204-19-000986","document":"tv509629_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000114420419000986/tv509629_4.xml","form_type":"4"}},{"id":3831591,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and Chief Medical Officer"}}],"security":"Common stock","published_at":"2018-08-28T16:33:09.000Z","date":"2018-08-24","kind":"purchase","acquired":true,"shares":500,"price":4.85,"value":2425.0,"ownership":{"direct":false,"nature":"By Meadowlark Management LLC"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose."}],"balance_after":1400,"source":{"system":"sec-edgar","filing":"0001551986-18-000017","document":"wf-form4_153548837301387.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000155198618000017/wf-form4_153548837301387.xml","form_type":"4"}},{"id":3831590,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and Chief Medical Officer"}}],"security":"Common stock","published_at":"2018-08-28T16:33:09.000Z","date":"2018-08-27","kind":"purchase","acquired":true,"shares":100,"price":4.94,"value":494.0,"ownership":{"direct":false,"nature":"By Meadowlark Management LLC"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose."}],"balance_after":900,"source":{"system":"sec-edgar","filing":"0001551986-18-000017","document":"wf-form4_153548837301387.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000155198618000017/wf-form4_153548837301387.xml","form_type":"4"}},{"id":3831589,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and Chief Medical Officer"}}],"security":"Common stock","published_at":"2018-08-28T16:33:09.000Z","date":"2018-08-27","kind":"purchase","acquired":true,"shares":253,"price":4.96,"value":1254.88,"ownership":{"direct":false,"nature":"By Meadowlark Management LLC"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose."}],"balance_after":800,"source":{"system":"sec-edgar","filing":"0001551986-18-000017","document":"wf-form4_153548837301387.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000155198618000017/wf-form4_153548837301387.xml","form_type":"4"}},{"id":3831588,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and Chief Medical Officer"}}],"security":"Common stock","published_at":"2018-08-28T16:33:09.000Z","date":"2018-08-27","kind":"purchase","acquired":true,"shares":47,"price":4.9,"value":230.3,"ownership":{"direct":false,"nature":"By Meadowlark Management LLC"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose."}],"balance_after":547,"source":{"system":"sec-edgar","filing":"0001551986-18-000017","document":"wf-form4_153548837301387.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000155198618000017/wf-form4_153548837301387.xml","form_type":"4"}},{"id":3831587,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and Chief Medical Officer"}}],"security":"Common stock","published_at":"2018-08-28T16:33:09.000Z","date":"2018-08-24","kind":"purchase","acquired":true,"shares":400,"price":4.99,"value":1996.0,"ownership":{"direct":false,"nature":"By Meadowlark Management LLC"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose."}],"balance_after":500,"source":{"system":"sec-edgar","filing":"0001551986-18-000017","document":"wf-form4_153548837301387.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000155198618000017/wf-form4_153548837301387.xml","form_type":"4"}},{"id":3831586,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and Chief Medical Officer"}}],"security":"Common stock","published_at":"2018-08-28T16:33:09.000Z","date":"2018-08-24","kind":"purchase","acquired":true,"shares":100,"price":4.85,"value":485.0,"ownership":{"direct":false,"nature":"By Meadowlark Management LLC"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0001551986-18-000017","document":"wf-form4_153548837301387.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492647/000155198618000017/wf-form4_153548837301387.xml","form_type":"4"}},{"id":3987883,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-20T14:50:35.000Z","date":"2018-03-15","kind":"purchase","acquired":true,"shares":5700,"price":3.5,"value":19950.0,"ownership":{"direct":false,"nature":"By Meadowlark Management LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4/A is being filed to reflect that this was an open market purchase of the Issuer's securities (On March 16, 2018 this transaction was incorrectly reported on Form 4 as an acquisition pursuant to Rule 16b-3(d)."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose."}],"balance_after":5700,"source":{"system":"sec-edgar","filing":"0001144204-18-015760","document":"tv488977_4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000114420418015760/tv488977_4a.xml","form_type":"4/A","original_submission_date":"2018-03-16"}},{"id":3992952,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-16T10:06:26.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":5700,"price":3.5,"value":19950.0,"ownership":{"direct":false,"nature":"By Meadowlark Management LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose."}],"balance_after":5700,"source":{"system":"sec-edgar","filing":"0001144204-18-015059","document":"tv488679_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000114420418015059/tv488679_4.xml","form_type":"4"}},{"id":4184074,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-10-18T18:01:18.000Z","date":"2017-10-16","kind":"grant","acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares of common stock subject to the stock option became exercisable immediately, and 1/3 of the shares of common stock subject to the stock option will become exercisable on each of\nOctober 16, 2018 and October 16, 2019."}],"balance_after":170000,"derivative":{"exercise_price":0.67,"expiration_date":"2022-10-15","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001387131-17-005087","document":"almenoff-form4_101617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1173281/000138713117005087/almenoff-form4_101617.xml","form_type":"4"}}]}